Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study


Galapagos NV (Euronext & NASDAQ: GLPG) announced additional long-term follow-up data for the investigational agent filgotinib in patients with moderate to severely active rheumatoid arthritis (RA) from the DARWIN 3 study. In this 84-week analysis of 560 patients representing 1,708 patient years of exposure, adverse events and treatment emergent lab abnormalities were consistent with prior safety results and filgotinib was shown to have durable activity; data are summarized in the abstract. These data and other filgotinib studies, as well as the Phase 1 First-in-Human results with Galapagos' investigational agent GLPG1972 in osteoarthritis, will be presented during the American College of Rheumatology Annual Meeting 2017 in San Diego, CA.

Following is an overview of all presentations on filgotinib at the ACR Annual Meeting 2017:

Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study, Mark C. Genovese, et al, #1909, Monday, Nov. 6, 2017, Session "Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Trials Therapy" 4:30 - 6:00pm PT

The JAK1 Selective Inhibitor Filgotinib Regulates Both Enthesis and Colon Inflammation in a Mouse Model of Psoriatic Arthritis, Catherine Robin-Jaegerschmidt et al, #497

Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients, Mark C. Genovese, et al, #1458

No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies, Arthur Cavanaugh et al, #537

Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study, Rene Westhovens et al, #534

Filgotinib, a Selective Janus Kinase 1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects, Kacey Anderson et al, #531

Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies, Mark C. Genovese et al, #510

Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients, Peter Taylor et al, #504

Lack of Drug-Drug Interaction between Filgotinib, a JAK-1 Selective Inhibitor, and a Representative Hormonal Contraceptive Medication, Levonorgestrel/Ethinyl Estradiol, Rebecca Begley et al, #1459

Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations, Iain B. McInnes et al, #2870

Filgotinib is an investigational therapy and its safety and efficacy have not been established.

GLPG1972 in osteoarthritis
Favorable Human Safety, Pharmacokinetics and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972, a Potential New Treatment in Osteoarthritis, Ellen van der Aar et al, poster #1189 to be presented on Monday 6 November 2017.


Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos' pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 578 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at



Interested in a regular update of the Life Sciences and biotech sector in Flanders?